A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. (Q51065459)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

main subject

phase II clinical trial

0 references

author

Janina Markowska

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2

Giovanni Scambia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

6

Isabelle Ray-Coquard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Thomas J Herzog

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Byoung-Gie Kim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Catherine Lhommé

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Jalid Sehouli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Nicoletta Colombo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Minghua Shan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Oana Petrenciuc

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Amit Oza

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

13 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

25-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

A review of the current evidence for maintenance therapy in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

The role of maintenance therapy and novel taxanes in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Overview of anti-angiogenic agents in development for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

A phase 3 trial of bevacizumab in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.011

10.1016/J.YGYNO.2013.04.011

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591401%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference